This is a routine operational update with no financial data or efficacy readout. Monitor for actual patient enrollment announcements and eventual Phase IIb data, but the current filing provides no catalyst for a directional trade.
Price Chart
Executive Summary
SciSparc subsidiary NeuroThera Labs announced operational progress in its FDA-approved Phase IIb trial of SCI-110 for Tourette Syndrome, including completion of investigational product manufacturing, European QP batch release certification, and site initiation at all three clinical sites. The milestone enables shipment of trial material and moves the program toward patient enrollment, but no efficacy or safety data were reported.
Key Facts
- NeuroThera completed manufacturing of investigational product for SCI-110 and obtained European QP batch release certification.
- All three clinical sites (Yale, Hannover Medical School, Tel Aviv Sourasky Medical Center) completed site initiation activities.
- Patient enrollment in the Phase IIb trial has not yet begun; investigational product shipments are expected in the near term.
- SCI-110 is a proprietary cannabinoid-based drug candidate combining dronabinol and palmitoylethanolamide (PEA).
- SciSparc's market cap is approximately $1M; the company had 365,444 ordinary shares outstanding as of December 31, 2025.
Financial Impact
No financial figures disclosed; operational milestone only.
Risk Factors
- Clinical-stage biotech with no approved products and minimal revenue.
- Extremely low market cap ($1M) and low share count (365K) create high volatility and liquidity risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-111852 |
| Document: ea030941001ex99-1.htm | 0001213900-26-111852 |
| Document: 0001213900-26-111852-index-headers.html | 0001213900-26-111852 |
| Document: 0001213900-26-111852-index.html | 0001213900-26-111852 |
| Document: 0001213900-26-111852.txt | 0001213900-26-111852 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.29 | awaiting T+5 | — | $1.29 (−0.04%) |
Oct 23, 2026 4d ago | 6-K | $1.09 | awaiting T+5 | — | $1.29 (+18.35%) |
Oct 22, 2026 4d ago | Press Release | $1.20 | awaiting T+5 | — | $1.29 (+7.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▲ +40.00% | ▲ +38.99% | $1.29 (+35.50%) |
Oct 15, 2026 11d ago | 6-K | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 15, 2026 12d ago | Press Release | $2.00 $1.20 | ▼ −40.00% | ▼ −38.99% | $1.29 (−35.50%) |
Oct 7, 2026 19d ago | 6-K | $4.64 $3.63 | ▼ −21.77% | ▼ −20.79% | $1.29 (−72.20%) |
Sep 30, 2026 26d ago | 6-K | $4.55 $4.43 | ▲ +2.64% | ▲ +3.94% | $1.29 (+71.65%) |
Sep 24, 2026 4w ago | 6-K | $5.39 $4.55 | ▼ −15.58% | ▼ −15.17% | $1.29 (−76.07%) |
Sep 23, 2026 4w ago | Press Release | $5.01 $4.72 | ▼ −5.79% | ▼ −5.11% | $1.29 (−74.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers